Newsroom

New Report Demonstrates Big Pharma’s Abuses of the Patent System

CSRxP spokesman Will Holley released the following statement on the release of I-MAK’s report, “Overpatented, Overpriced: How Excessive Pharmaceutical Patenting is Extending Monopolies and Driving up Drug […]

Read more

High Priced Drugs Lead to Banner Q2 Earnings for Big Pharma

CSRxP released the following statement following a week of strong Q2 earnings across the branded pharma sector: “While patients throughout the nation continue to suffer from […]

Read more

CSRxP on Lilly & Biogen Earnings

CSRxP released the following statement following the release of Eli Lilly and Biogen’s Q2 earnings today: “Out-of-control prescription drug prices are fueling profits for brand-name drug […]

Read more

CSRxP Applauds Admin Focus on Drug Prices

CSRxP spokesman Will Holley released the following statement applauding the Trump Administration’s focus on drug prices and the recent positive announcements from certain brand-name drug manufacturers: […]

Read more